Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-08-06

Clinical Trial Update: IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Lower Grade Glioma [Phase 1]

View source ↗

Summary

Phase 1 study of the imaging agent IRDye800CW-BBN for guiding surgery in lower-grade glioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IRDye800CW-BBN (IRDye800CW-BBN conjugate imaging agent)

Snippet

Sponsor: Deling Li | Conditions: Glioma | Phase 1 | Status: COMPLETED